Home › Research › Topics › synthase-kinase-3
synthase-kinase-3
4 studies tagged synthase-kinase-3, dated 2004-01-01 to 2017-02-15. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3β 2017-02-15
- Phosphatidylinositol 3-kinase (PI3K) signaling via glycogen synthase kinase-3 (Gsk-3) regulates DNA methylation of imprinted loci 2010-11-03
- Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors 2010-05-01
Studies
4 studies carry this tag.
Date range
2004 to 2017
Top journals
- American journal of translational research 1
- Expert review of neurotherapeutics 1
- The Journal of biological chemistry 1
- The Journal of clinical psychiatry 1
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Memory deterioration and synapse damage with accumulation of β-amyloid and hyperphosphorylated tau are hallmark lesions of Alzheimer's disease (AD).
-
Glycogen synthase kinase-3 (Gsk-3) isoforms, Gsk-3α and Gsk-3β, are constitutively active, largely inhibitory kinases involved in signal transduction.
-
Glycogen synthase kinase (GSK)-3 has been proposed as the link between the two histopathological hallmarks of Alzheimer's disease, the extracellular senile plaques composed of beta-amyloid and the intracellular neurofibrillary tangles formed from hyperphosphorylated tau.
-
The enzyme glycogen synthase kinase-3 (GSK-3) is a direct target of lithium.